Better Buy: Johnson & Johnson vs. AbbVie
It's been a neck-and-neck race between Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) stocks so far in 2017. The two healthcare stocks are up by nearly identical levels year to date. And that's despite revenue headwinds for J&J and strong sales growth for AbbVie.
Which of these two stocks is the better buy right now? The primary criteria for investors to grade the companies on include current products, growth prospects, dividend strength, and valuation. Here's how Johnson & Johnson and AbbVie compare.
Image source: Getty Images.
Source: Fool.com
Johnson & Johnson Stock
€229.30
-1.940%
With 57 Buy predictions and not a single Sell prediction Johnson & Johnson is an absolute favorite of our community.
At the moment Johnson & Johnson has reached the predicted target price of 230 €, with a current price of 229.3 €.
